Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, has commenced a clinical study to investigate the use of OCT to diagnose basal cell carcinoma in collaboration with the Melanoma Institute of Australia using Michelson's Diagnostics VivoSight system.
The study, run by Dr Pascale Guitera FACD PhD, will evaluate VivoSight's ability to triage lesions which are superficial enough to be treated non-invasively and monitor the success, or otherwise, of non-invasive therapies. The study is designed to determine the potential to change clinical practice towards more non-invasive treatments of basal cell carcinoma enabled by OCT. The study is expected to complete in 2015.
In addition, Michelson Diagnostics has received registration from the Australia Therapeutic Goods Administration for the VivoSight OCT scanner. Simon Luscombe of Momentum Medical will act as Michelson Diagnostics' representative for the launch of VivoSight in Australia. The Company will be exhibiting VivoSight at the Australian College of Dermatologists Annual Scientific Meeting in Melbourne, 18-21 May.
Dr Pascale Guitera, lead investigator at the Melanoma Institute of Australia. Dr Guitera said: “I have a passion for cutting-edge techniques that enable non-invasive diagnosis of skin tumours. VivoSight has the potential to radically change the way in which we practice to allow non-invasive treatment regimes.”
Jon Holmes, CEO of Michelson Diagnostics, added: “We are delighted to be working with Dr Guitera and the Melanoma Institute of Australia. She is one of the top ten world experts in her field. We believe that our VivoSight system is the future of tumour diagnosis and monitoring and we looking forward to reporting the results in due course.”